Katharina Seystahl Selected Research

Neoplasms (Cancer)

4/2024	Glioblastoma in the oldest old: Clinical characteristics, therapy, and outcome in patients aged 80 years and older.
1/2024	A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol.
4/2023	Stroke-associated infections in patients with and without cancer.
2/2022	Feasibility of glioblastoma tissue response mapping with physiologic BOLD imaging using precise oxygen and carbon dioxide challenge.
1/2022	Venous thromboembolic events in glioblastoma patients: An epidemiological study.
11/2021	Cancer is associated with inferior outcome in patients with ischemic stroke.
6/2021	Endoglin and TGF-β signaling in glioblastoma.
1/2020	Hemodynamic investigation of peritumoral impaired blood oxygenation-level dependent cerebrovascular reactivity in patients with diffuse glioma.
1/2019	Response assessment of meningioma: 1D, 2D, and volumetric criteria for treatment response and tumor progression.
12/2016	Limited role for transforming growth factor-β pathway activation-mediated escape from VEGF inhibition in murine glioma models.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Katharina Seystahl Research Topics

Disease

18	Glioblastoma (Glioblastoma Multiforme) 04/2024 - 05/2012
15	Neoplasms (Cancer) 04/2024 - 01/2012
8	Glioma (Gliomas) 06/2021 - 01/2013
3	Meningioma (Meningiomas) 01/2019 - 03/2016
2	Seizures (Absence Seizure) 01/2024 - 01/2022
2	Venous Thromboembolism 01/2022 - 11/2021
2	Brain Neoplasms (Brain Tumor) 01/2022 - 01/2022
2	Necrosis 04/2021 - 01/2016
2	Hemangioblastoma 01/2014 - 01/2012
1	Epilepsy (Aura) 01/2024
1	Stroke (Strokes) 04/2023
1	Infections 04/2023
1	Nausea 01/2022
1	Vomiting 01/2022
1	Fatigue 01/2022
1	Edema (Dropsy) 03/2016
1	Brain Edema (Cerebral Edema) 03/2016
1	Hypoxia (Hypoxemia) 02/2015
1	Cysts 02/2014
1	Lymphoma (Lymphomas) 09/2012
1	Leukemia 09/2012

Drug/Important Bio-Agent (IBA)

8	Bevacizumab (Avastin)FDA Link 11/2022 - 01/2012
6	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2021 - 01/2012
5	Biomarkers (Surrogate Marker)IBA 04/2023 - 02/2015
3	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2017 - 02/2015
2	C-Reactive ProteinIBA 04/2023 - 11/2021
2	Irinotecan (Camptosar)FDA LinkGeneric 03/2020 - 01/2013
2	Temozolomide (Temodar)FDA LinkGeneric 06/2016 - 01/2013
2	cediranib (AZD2171)IBA 01/2016 - 05/2012
1	Memantine (Namenda)FDA Link 01/2024
1	Glutamic Acid (Glutamate)FDA Link 01/2024
1	Neurotransmitter Agents (Neurotransmitter)IBA 01/2024
1	Gabapentin (Neurontin)FDA LinkGeneric 01/2024
1	SteroidsIBA 01/2024
1	Sulfasalazine (Azulfidine)FDA LinkGeneric 01/2024
1	O-(6)-methylguanineIBA 01/2024
1	DNA (Deoxyribonucleic Acid)IBA 01/2024
1	MethyltransferasesIBA 01/2024
1	ProcalcitoninIBA 04/2023
1	Proteins (Proteins, Gene)FDA Link 04/2023
1	AlbuminsIBA 04/2023
1	Oxygen (Dioxygen)IBA 02/2022
1	Carbon DioxideIBA 02/2022
1	Levetiracetam (Keppra)FDA LinkGeneric 01/2022
1	AnticoagulantsIBA 01/2022
1	vinyltriethoxysilane (VTES)IBA 01/2022
1	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2022
1	Anticonvulsants (Antiepileptic Drugs)IBA 01/2022
1	Hemoglobins (Hemoglobin)IBA 11/2021
1	EndoglinIBA 06/2021
1	LigandsIBA 06/2021
1	Alkylating AgentsIBA 03/2020
1	thiamine triphosphorate (TTP)IBA 01/2020
1	Plasminogen InactivatorsIBA 01/2017
1	Antisense OligonucleotidesIBA 01/2017
1	Messenger RNA (mRNA)IBA 01/2017
1	Protein Isoforms (Isoforms)IBA 01/2017
1	LY-2157299IBA 12/2016
1	Somatostatin Receptors (Somatostatin Receptor)IBA 11/2016
1	Radioisotopes (Radionuclides)IBA 11/2016
1	Edotreotide (SMT 487)IBA 11/2016
1	Antineoplastic Agents (Antineoplastics)IBA 03/2016
1	Matrix Metalloproteinase 9 (Gelatinase B)IBA 01/2016
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2016
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2016
1	Tyrosine Kinase InhibitorsIBA 01/2016
1	Neutralizing AntibodiesIBA 01/2016
1	Lomustine (CCNU)FDA Link 10/2014
1	CytokinesIBA 09/2012
1	Dasatinib (BMS 354825)FDA Link 09/2012
1	Angiogenesis InhibitorsIBA 05/2012
1	afliberceptIBA 05/2012
1	enzastaurinIBA 05/2012

Therapy/Procedure

6	Therapeutics 04/2024 - 01/2014
4	Radiotherapy 04/2021 - 01/2013
4	Drug Therapy (Chemotherapy) 03/2020 - 01/2013
3	Chemoradiotherapy 01/2024 - 01/2022
2	Aftercare (After-Treatment) 01/2019 - 01/2012
1	Terminal Care (Care, Terminal) 05/2020
1	Immunotherapy 03/2016
1	Ventriculostomy 02/2014